Symbols

RLAY

Relay Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RLAY

Relay Therapeutics, Inc.

A clinical-stage precision medicine company that develops commercializes small molecule therapies for the treatment of solid tumors cancer

Industry

Biological Technology

Established Date

05/04/2015

Listing Date

07/16/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

192

Fiscal Year Ends

12-31

Website

www.relaytx.com

Security Type

Common stock

Office address

60 Hampshire Street, Cambridge, MA 02139

Business

Introduction

Relay Therapeutics, Inc., was incorporated in Delaware on May 4, 2015. The company is a clinical-stage precision pharmaceutical company dedicated to transforming the drug discovery process, with an initial focus on enhancing small-molecule therapeutic discoveries in targeted oncology. The company is built on unparalleled insight into protein movement and the relationship between this dynamic behavior and protein function. The company's Dynamo platform integrates a range of advanced experimental and computational methods, allowing the company to apply its understanding of protein structure and movement to drug development. The company is developing its lead product candidates RLY-4008 and RLY-1971, and is developing drug candidates for the PI 3Kα Selective Mutant Program (RLY-PI 3K1047 Program) to treat patients with advanced solid tumors.

Company Financials

EPS

RLAY has released its 2025 Q4 earnings. EPS was reported at -0.32, versus the expected -0.41, beating expectations. The chart below visualizes how RLAY has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RLAY has released its 2025 Q4 earnings report, with revenue of 7.00M, reflecting a YoY change of NaN%, and net profit of -54.89M, showing a YoY change of 27.78%. The Sankey diagram below clearly presents RLAY's revenue sources and cost distribution.